Lucence Diagnostics Launches LiquidHALLMARK® Test in Asia for Detecting Multiple Cancer-Causing Mutations and Viruses

In Media Releases
October 24, 2018

Lucence Diagnostics, a genomic medicine company focused on personalizing cancer care, today announced the availability of the world’s first blood test that detects multiple cancer-related mutations and viral targets for clinical use in Asia. The LiquidHALLMARK® test helps physicians to select targeted therapies and monitor treatment response.

This liquid biopsy panel identifies clinically relevant genomic alterations including somatic mutations, microsatellite instability (MSI) and viral DNA from circulating tumor DNA (ctDNA) in blood. The test is designed for cancers that are more prevalent in Asia, including breast, colon, lung and nasopharyngeal cancers, among others.

LiquidHALLMARK® matches the genomic alterations in each patient’s tumor to targeted drugs for more effective treatment. The presence of MSI helps to predict whether the tumor will respond well to immunotherapy, and the detection of cancer-associated viruses such as the Epstein-Barr virus (EBV) enables the diagnosis of nasopharyngeal cancer.

The test is based on Lucence’s proprietary molecular watermarking technology AmpliMARK™ with sensitivity and specificity of up to 99.9%. This sequencing technology is supported by the company’s AI-powered clinical analytics engine SunTzu.AI™.

Lucence is also developing a blood test for the early detection of multiple cancers prevalent in Asia using this technology. This is aimed at reducing avoidable cancer death, which is globally highest in Asia.

“Lucence is excited to launch our flagship LiquidHALLMARK® test throughout Asia to improve cancer diagnosis and treatment. Our test delivers comprehensive molecular profiling of tumor with just one draw of blood. This is the first test in the world that simultaneously detects multiple cancer-causing mutations and viruses to maximize options for patients. LiquidHALLMARK® will enable us to provide personalized cancer care for better treatment outcomes,” said Dr. Min-Han Tan, Founder and CEO, Lucence Diagnostics.

The validation data of LiquidHALLMARK® was first published at the American Society of Clinical Oncology Meeting (ASCO) in June 2018.

For more information, please contact:

Lucence Diagnostics
Elena Tan
Tel: +65 6592 5102
Email: [email protected]

About Lucence Diagnostics

Lucence Diagnostics is a genomic medicine company focused on personalizing cancer care. Headquartered in Singapore with offices in Hong Kong and San Francisco, Lucence invents genomic tests that enable earlier cancer diagnosis and better treatment selections. Lucence’s tests target the most common cancers in Asia using proprietary technology and clinical analytics. Its key operations are supported by an ISO 15189 accredited molecular diagnostics laboratory and a cancer genetics clinic. For more information, please visit www.lucencedx.com.

Need Help?